AccessPak for HIV PEP Expanded with Viracept and Menactra

• Generic Name: emtricitabine / nelfinavir / tenofovir
• Dosage Forms: n.a.
• Other Brand Names: AccessPak for HIV PEP Expanded with Viracept

AccessPak for HIV PEP Expanded with Viracept are antiviral drugs that prevent human immunodeficiency virus (HIV) from multiplying in your body.

AccessPak for HIV PEP Expanded with Viracept is a combination medicine used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). AccessPak for HIV PEP Expanded with Viracept is not a cure for HIV or AIDS.

This medicine may also be used together with safer-sex practices to reduce the risk of becoming infected with HIV. You must be HIV-negative and an adult to use the medicine for this purpose. AccessPak for HIV PEP Expanded with Viracept may not provide protection from disease in every person.

AccessPak for HIV PEP Expanded with Viracept may also be used for purposes not listed in this medication guide.

• Generic Name: meningococcal conjugate vaccine
• Dosage Forms: n.a.
• Other Brand Names: Menactra, Menveo

Menactra (meningococcal conjugate vaccine) is used to prevent infection caused by meningococcal bacteria.

Menactra works by exposing you to a small dose of the bacteria or a protein from the bacteria, which causes your body to develop immunity to the disease. Meningococcal conjugate vaccine contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y).

Meningococcal disease is a serious infection caused by a bacteria. Meningococcal bacteria can infect the spinal cord and brain, causing meningitis that can be fatal. Meningococcal disease can also lead to permanent and disabling medical problems.

Meningococcal disease can spread from one person to another through small droplets of saliva that are expelled into the air when an infected person coughs or sneezes. The bacteria can also be passed through contact with objects the infected person has touched, such as a door handle or other surface. The bacteria can also be passed through kissing, or sharing a drinking glass or eating utensil with an infected person.

Meningococcal disease is more likely to occur in babies younger than 1 year, in young people ages 16 to 23 years, in anyone with a weak immune system, those without a functioning spleen, and in anyone exposed to an outbreak of the disease.

Menactra is used to prevent infection caused by meningococcal bacteria. The vaccine works by exposing you to a small dose of the bacteria or a protein from the bacteria, which causes your body to develop immunity to the disease. Menactra contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y).

Menactra will not treat an active meningococcal infection that has already developed in the body.

Menactra is for use in children and adults between the ages of 9 months and 55 years old.

Like any vaccine, Menactra may not provide protection from disease in every person.